Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Tremelimumab, and Radiation in Recurrent/Metastatic HNSCC
NCT03522584Phase 2Terminated
- Sponsor
- University of Washington
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Washington. Primary endpoint: Number of Patients With Adverse Effects Graded According to CTCAE v. 4.0 at 38 months. Started May 2018; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03522584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522584.